CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-03-14 | Bowden Christopher Chief Medical Officer | Option exercise | +2,000 | $35.16 | $70K | 2,881 |
| 2018-03-14 | Bowden Christopher Chief Medical Officer | Sale | −1,700 | $82.23 | $140K | 1,181 |
| 2018-03-14 | Bowden Christopher Chief Medical Officer | Sale | −300 | $82.90 | $25K | 881 |
| 2018-03-14 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −2,000 | 103,000 | ||
| 2018-03-05 | Biller Scott Chief Scientific Officer | Option exercise | +3,000 | $9.05 | $27K | 56,059 |
| 2018-03-05 | Biller Scott Chief Scientific Officer | Sale | −400 | $80.93 | $32K | 55,659 |
| 2018-03-05 | Biller Scott Chief Scientific Officer | Sale | −400 | $82.04 | $33K | 55,259 |
| 2018-03-05 | Biller Scott Chief Scientific Officer | Sale | −1,100 | $83.21 | $92K | 54,159 |
| 2018-03-05 | Biller Scott Chief Scientific Officer | Sale | −1,100 | $84.10 | $93K | 53,059 |
| 2018-03-05 | Biller Scott Chief Scientific Officer | Option exercise · Stock options (right to buy) | −3,000 | 28,154 | ||
| 2018-03-01 | Schenkein David P Chief Executive Officer | Option exercise | +13,000 | $0.30 | $4K | 13,000 |
| 2018-03-01 | Schenkein David P Chief Executive Officer | Sale | −2,915 | $80.38 | $234K | 10,085 |
| 2018-03-01 | Schenkein David P Chief Executive Officer | Sale | −10,085 | $81.30 | $820K | 0 |
| 2018-03-01 | Schenkein David P Chief Executive Officer | Option exercise · Stock option (right to buy) | −13,000 | 91,567 | ||
| 2018-02-26 | Foster-Cheek Kaye I Director | Option exercise | +2,200 | $47.33 | $104K | 2,200 |
| 2018-02-26 | Foster-Cheek Kaye I Director | Option exercise · Stock option (right to buy) | −2,200 | 6,800 | ||
| 2018-02-22 | Hoerter Steven L. Chief Commercial Officer | Option exercise | +2,050 | $39.76 | $82K | 2,050 |
| 2018-02-22 | Hoerter Steven L. Chief Commercial Officer | Sale | −2,050 | $78.63 | $161K | 0 |
| 2018-02-22 | Hoerter Steven L. Chief Commercial Officer | Option exercise · Stock option (right to buy) | −2,050 | 72,950 | ||
| 2018-02-16 | Alenson Carman Principal Accounting Officer | Grant or award · Stock option (right to buy) | +9,480 | 9,480 |
Page 65 of 80 · 1,590 trades